ASC Investment ROI Calculator
You've been offered equity in an ambulatory surgery center. The buy-in is real money — $200K, $400K, sometimes more. What you get back in distributions over the next decade, and what your stake is worth when the ASC sells, is where ortho surgeons build serious wealth. Enter your actual numbers to model the full picture.
How to read these results
Net cash this year is your distribution minus your loan payment (if financed). Year 1 also deducts the cash portion of your buy-in — that's the capital you put in on day one.
Cumulative cash is the running total. When it turns positive, you've broken even on the investment from distributions alone — before any exit. Most well-structured ortho ASC investments break even on distributions within 2–5 years.
Exit proceeds are modeled as your final-year distribution × your exit multiple. This is a reasonable proxy because ASCs are generally valued on a multiple of distributable cash flow (EBITDA), and your share of distributions approximates your share of EBITDA. At exit, add the exit proceeds to your cumulative cash total for your full return.
IRR is the annualized return on invested capital across all cash flows, including exit. This is the number to compare against other investment opportunities — private equity funds, index funds, real estate, etc. Well-structured ortho ASC investments have historically produced IRRs in the 20–50%+ range when exit multiples are strong.
- After-tax distributions. ASC distributions on a K-1 are ordinary income at your marginal rate (37% federal for most ortho surgeons). Exit proceeds may be taxed as long-term capital gains (23.8% combined federal for high earners: 20% + 3.8% NIIT). The pre-tax vs after-tax gap matters enormously over a 10-year hold.
- QBI deduction eligibility. Whether your ASC interest qualifies for the Section 199A pass-through deduction depends on entity structure and your income level — worth $30–70K/yr in additional deduction for surgeons in the right structure.
- ASC valuation quality. The buy-in price you're offered reflects someone's valuation of the ASC. An independent analysis often reveals whether you're buying in at fair value, at a premium, or (rarely) at a discount. Orthopedic groups sometimes use new-surgeon buy-ins to recapitalize at above-market valuations.
- Federal Stark Law and Anti-Kickback safe harbors. Physician ownership in ASCs must qualify under specific regulatory safe harbors. Your interest percentage and ownership structure must comply — a specialist advisor who works with physicians knows these rules cold.
- What happens if you leave the group. Partnership agreements vary widely on forced buyouts, put/call provisions, and what you receive if you retire or move to hospital employment. Read the operating agreement before writing the check.
What makes a good ASC investment?
Not all ASC equity stakes are equal. Here's what experienced advisors look for:
- Payback period under 3 years. A buy-in that pays back purely from distributions within 3 years is strong. 3–5 years is solid. Over 5 years warrants scrutiny of case volume trends.
- Fair entry valuation. Orthopedic ASCs selling equity to new surgeons should be priced at a multiple consistent with their actual EBITDA. Verify this independently — groups have been known to mark up buy-in prices when adding a new partner.
- Case volume trajectory. Distributions grow with case volume. An ASC adding new service lines (robotics, spine, total joints) has a different growth profile than one running at capacity with no expansion planned.
- Payer mix. Commercial and self-pay cases generate 3–5× what Medicare cases do. A predominantly Medicare spine center will have different economics than a commercial-heavy sports medicine center.
- Strategic exit path. USPI, SurgCenter Development (now part of Tenet/USPI2), hospital systems, and private equity are all active acquirers. An ASC with no plausible exit path constrains your upside.
Related tools and guides
Frequently Asked Questions
How much does it cost to buy into an ASC as an orthopedic surgeon?
Orthopedic ASC buy-ins typically range from $100,000 to $600,000+, depending on center size, case volume, payer mix, and how many equity shares are available. High-volume ortho centers in competitive markets often command buy-ins of $300,000–$600,000. The price reflects the ASC's equity value divided by the ownership percentage being offered — use the calculator above to model your specific scenario.
What is a typical annual ASC distribution for an orthopedic surgeon?
Annual distributions vary widely by case volume and payer mix, but $100,000–$600,000 per year is a typical range for orthopedic ASC partners. High-volume spine surgeons at profitable multi-surgeon centers often see $300,000–$700,000 annually. Commercial-heavy case mixes (sports medicine, elective joint replacement) generate 3–5× more per case than Medicare-dominant centers.
How long does it take to break even on an ASC investment?
Most well-structured orthopedic ASC investments break even on distributions alone within 2–5 years. A $300,000 buy-in generating $175,000 per year in distributions breaks even in under 2 years. Beyond the distribution break-even, exit proceeds at a typical 6–10× multiple add substantial additional return that pure distribution math understates.
What EBITDA multiple do orthopedic ASCs sell at?
Orthopedic ASCs typically sell at 6–10× EBITDA for single-specialty centers, and up to 12× for high-volume multi-specialty facilities. Recent strategic acquisitions by USPI/Tenet and hospital systems have pushed multiples higher in markets with strong commercial payer mix. Single-specialty spine centers with consistent case volume often trade at 8–10×.
Can I finance an ASC buy-in?
Yes. Physician-focused lenders regularly finance ASC buy-ins at 5–7 year terms with competitive rates, given the strong income profile of orthopedic surgeons. Some ASC operating agreements also allow seller financing — a direct note to the partnership — which avoids bank fees and may offer more flexible terms. The calculator above models both all-cash and partially-financed scenarios side by side.
Is ASC distribution income taxed as ordinary income or capital gains?
ASC distributions are typically reported on a Schedule K-1 as ordinary income from a partnership, taxed at your marginal rate (37% federal for most ortho surgeons earning $600,000+). Exit proceeds from selling your ASC equity stake held more than 12 months may qualify as long-term capital gains at 23.8% combined federal rate (20% LTCG + 3.8% NIIT), representing a major tax advantage at exit compared to ordinary distribution income.
What is the Stark Law safe harbor for physician ASC ownership?
Physician ownership in an ASC qualifies for the Anti-Kickback Statute safe harbor under 42 C.F.R. § 1001.952(r) when the investment is offered at fair market value, terms are not based on referral volume, and the ASC meets specific governance criteria. A healthcare attorney must review the operating agreement before you invest — noncompliant ownership structures carry significant legal and financial risk.
What return on investment should I expect from an orthopedic ASC?
Well-structured orthopedic ASC investments have historically produced IRRs of 20–50%+ when exit multiples are strong. Your actual IRR depends on the buy-in price, annual distribution level, distribution growth rate, and the exit multiple achieved. The calculator above computes your specific annualized IRR using all cash flows including the terminal exit — compare it against other investment opportunities to evaluate the ASC objectively.
What happens to my ASC equity if I leave the group?
Departure provisions are governed by your ASC operating agreement and typically include: a right of first refusal for remaining partners, a forced buyout at a formula price based on trailing EBITDA or distributions, and sometimes minimum case-volume requirements to preserve your stake. Review these clauses before investing — especially if a non-compete clause could prevent you from sustaining the case volume your equity requires.
Should ASC equity be evaluated separately from the practice partnership buy-in?
Yes, always. ASC equity should be independently valued based on ASC-specific EBITDA, payer mix, case volume trends, and comparable transaction multiples — not bundled into a blended practice buy-in price. The AKS safe harbor requires ASC interests to be offered at fair market value, meaning a defensible FMV analysis should be available. Bundling makes it impossible to evaluate whether the ASC component is fairly priced relative to the practice goodwill.
Have a specific ASC investment to evaluate?
A specialist advisor will review the operating agreement, validate the entry valuation, model after-tax returns, and flag anything that could cost you at exit. Free match, no obligation.
- FOCUS Investment Banking, Ambulatory Surgery Center EBITDA Multiples 2026 Report — single-specialty ASCs 5–8×, multi-specialty 6–10×, with landmark USPI/SurgCenter transaction at 10.8×. focusbankers.com
- Tenet Healthcare committed nearly $1.5B to acquire 92 SurgCenter ASCs in 2025–2026. Fierce Healthcare
Market figures verified April 2026. Exit multiples are estimates; actual transaction pricing varies by center size, case mix, payer mix, and acquirer. All calculator outputs are pre-tax gross figures.